Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2021 · 10-Q
Revenue$2.36M$2.36M+33.7% vs Q1 2020 Net Income-$767.33K-$767.33KN/M vs Q1 2020 EPS Diluted-$0.02-$0.02N/M vs Q1 2020 Gross Profit$272,730+40.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$276,916N/M Margins · derivedGross margin11.6%+0.5 pt vs Q1 2020
Operating margin-29.5%+4.4 pt vs Q1 2020
Net margin-32.5%+4.9 pt vs Q1 2020
ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end